RhumbLine Advisers’s NRC Health Common Stock NRC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $262K | Sell |
15,437
-434
| -3% | -$7.38K | ﹤0.01% | 2983 |
|
|
2025
Q4 | $298K | Sell |
15,871
-4,812
| -23% | -$72.6K | ﹤0.01% | 2975 |
|
|
2025
Q3 | $264K | Sell |
20,683
-1,091
| -5% | -$16.4K | ﹤0.01% | 3076 |
|
|
2025
Q2 | $366K | Sell |
21,774
-430
| -2% | -$5.81K | ﹤0.01% | 2874 |
|
|
2025
Q1 | $284K | Buy |
22,204
+946
| +4% | +$15.2K | ﹤0.01% | 2922 |
|
|
2024
Q4 | $375K | Sell |
21,258
-365
| -2% | -$6.92K | ﹤0.01% | 2847 |
|
|
2024
Q3 | $494K | Buy |
21,623
+170
| +0.8% | +$3.84K | ﹤0.01% | 2703 |
|
|
2024
Q2 | $492K | Buy |
21,453
+892
| +4% | +$27.5K | ﹤0.01% | 2692 |
|
|
2024
Q1 | $814K | Buy |
20,561
+457
| +2% | +$18.1K | ﹤0.01% | 2370 |
|
|
2023
Q4 | $795K | Buy |
20,104
+457
| +2% | +$19.1K | ﹤0.01% | 2388 |
|
|
2023
Q3 | $872K | Buy |
19,647
+316
| +2% | +$13.8K | ﹤0.01% | 2289 |
|
|
2023
Q2 | $841K | Buy |
19,331
+272
| +1% | +$12K | ﹤0.01% | 2393 |
|
|
2023
Q1 | $829K | Buy |
19,059
+1,256
| +7% | +$55.5K | ﹤0.01% | 2211 |
|
|
2022
Q4 | $664K | Buy |
17,803
+155
| +0.9% | +$6K | ﹤0.01% | 2337 |
|
|
2022
Q3 | $702K | Buy |
17,648
+1,190
| +7% | +$44.1K | ﹤0.01% | 2339 |
|
|
2022
Q2 | $630K | Buy |
16,458
+2,173
| +15% | +$78.6K | ﹤0.01% | 2369 |
|
|
2022
Q1 | $566K | Buy |
14,285
+27
| +0.2% | +$1.06K | ﹤0.01% | 2365 |
|
|
2021
Q4 | $592K | Sell |
14,258
-244
| -2% | -$10.6K | ﹤0.01% | 2443 |
|
|
2021
Q3 | $612K | Buy |
14,502
+435
| +3% | +$21.9K | ﹤0.01% | 2448 |
|
|
2021
Q2 | $646K | Sell |
14,067
-1,031
| -7% | -$49K | ﹤0.01% | 2437 |
|
|
2021
Q1 | $707K | Sell |
15,098
-1,154
| -7% | -$56.1K | ﹤0.01% | 2342 |
|
|
2020
Q4 | $695K | Buy |
16,252
+890
| +6% | +$45.7K | ﹤0.01% | 2302 |
|
|
2020
Q3 | $756K | Sell |
15,362
-2,217
| -13% | -$123K | ﹤0.01% | 2100 |
|
|
2020
Q2 | $1.02M | Buy |
17,579
+2,134
| +14% | +$113K | ﹤0.01% | 2034 |
|
|
2020
Q1 | $702K | Buy |
15,445
+81
| +0.5% | +$4.87K | ﹤0.01% | 2027 |
|
|
2019
Q4 | $1.01M | Buy |
15,364
+335
| +2% | +$20.5K | ﹤0.01% | 2080 |
|
|
2019
Q3 | $868K | Buy |
15,029
+270
| +2% | +$16.7K | ﹤0.01% | 2107 |
|
|
2019
Q2 | $850K | Buy |
14,759
+905
| +7% | +$41.9K | ﹤0.01% | 2127 |
|
|
2019
Q1 | $535K | Sell |
13,854
-464
| -3% | -$18.2K | ﹤0.01% | 2307 |
|
|
2018
Q4 | $546K | Buy |
14,318
+4,849
| +51% | +$186K | ﹤0.01% | 2257 |
|
|
2018
Q3 | $366K | Sell |
9,469
-650
| -6% | -$24.6K | ﹤0.01% | 2411 |
|
|
2018
Q2 | $378K | Buy |
10,119
+1,545
| +18% | +$53.8K | ﹤0.01% | 2434 |
|
|
2018
Q1 | $251K | Sell |
8,574
-300
| -3% | -$10.1K | ﹤0.01% | 2522 |
|
|
2017
Q4 | $331K | Sell |
8,874
-1,743
| -16% | -$61.9K | ﹤0.01% | 2418 |
|
|
2017
Q3 | $400K | Buy |
10,617
+150
| +1% | +$4.71K | ﹤0.01% | 2422 |
|
|
2017
Q2 | $282K | Sell |
10,467
-697
| -6% | -$17K | ﹤0.01% | 2589 |
|
|
2017
Q1 | $220K | Buy |
11,164
+392
| +4% | +$7.25K | ﹤0.01% | 2622 |
|
|
2016
Q4 | $205K | Buy |
10,772
+455
| +4% | +$7.51K | ﹤0.01% | 2663 |
|
|
2016
Q3 | $168K | Buy |
+10,317
| New | +$162K | ﹤0.01% | 2732 |
|
|
2016
Q2 | – | Sell |
-10,963
| Closed | -$170K | – | 3011 |
|
|
2016
Q1 | $170K | Buy |
10,963
+45
| +0.4% | +$660 | ﹤0.01% | 2786 |
|
|
2015
Q4 | $175K | Buy |
10,918
+850
| +8% | +$12.9K | ﹤0.01% | 2844 |
|
|
2015
Q3 | $120K | Buy |
+10,068
| New | +$134K | ﹤0.01% | 2917 |
|
|
2015
Q2 | – | Sell |
-10,578
| Closed | -$152K | – | 3066 |
|
|
2015
Q1 | $152K | Buy |
+10,578
| New | +$149K | ﹤0.01% | 2892 |
|
|
2014
Q2 | – | Sell |
-10,380
| Closed | -$172K | – | 3052 |
|
|
2014
Q1 | $172K | Sell |
10,380
-450
| -4% | -$7.54K | ﹤0.01% | 2821 |
|
|
2013
Q4 | $204K | Sell |
10,830
-500
| -4% | -$8.77K | ﹤0.01% | 2805 |
|
|
2013
Q3 | $213K | Sell |
11,330
-109
| -1% | -$1.87K | ﹤0.01% | 2747 |
|
|
2013
Q2 | $206K | Buy |
+11,439
| New | +$183K | ﹤0.01% | 2966 |
|
Other funds holding NRC
VCM
QI
RhumbLine Advisers's NRC Position: Q1 2026 in Review
RhumbLine Advisers reduced its NRC Health Common Stock (NRC) stake by 2.7% in Q1 2026, selling an estimated $7.38K and leaving 15,437 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #2983.
RhumbLine Advisers first reported a position in NRC in Q2 2013 and has held it in 47 quarters since. The position peaked at $1.02M in Q2 2020. 121 funds tracked by Wall St. Rank hold NRC as of Q1 2026.
- RhumbLine Advisers held 15,437 shares of NRC Health Common Stock worth $262K as of Q1 2026.
- RhumbLine Advisers sold 434 NRC Health Common Stock shares in Q1 2026, an estimated $7.38K.
- NRC Health Common Stock made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2983 holding.
- RhumbLine Advisers first reported a position in NRC Health Common Stock in Q2 2013 and has held it in 47 quarters since.
- RhumbLine Advisers's NRC Health Common Stock position peaked at $1.02M in Q2 2020.
- 121 funds tracked by Wall St. Rank held NRC Health Common Stock as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.